EuBiologics Co. Ltd.
EuBiologics Co., Ltd., a biopharmaceutical company, focuses on developing vaccines against global pandemic and bacterial vaccines primarily in South Korea. It offers inactivated oral cholera vaccine under the Euvichol, Euvichol-Plus, and Euvichol-S names; and EuCorVac-19, a recombinant protein vaccine. The company also provides EcML that is used as a vaccine adjuvant, directly activating antigen … Read more
EuBiologics Co. Ltd. (206650) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.113x
Based on the latest financial reports, EuBiologics Co. Ltd. (206650) has a cash flow conversion efficiency ratio of 0.113x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩19.58 Billion) by net assets (₩173.74 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
EuBiologics Co. Ltd. - Cash Flow Conversion Efficiency Trend (2021–2024)
This chart illustrates how EuBiologics Co. Ltd.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
EuBiologics Co. Ltd. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of EuBiologics Co. Ltd. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Alma Media Oyj
HE:ALMA
|
0.088x |
|
Schweizerische Nationalbank
PINK:SWZNF
|
0.000x |
|
Hg Technologies Co Ltd
SHE:300847
|
0.032x |
|
Hengong Precision Equipment Co Ltd
SHE:301261
|
N/A |
|
Harworth Group plc
PINK:HWGLF
|
N/A |
|
AES Brasil Energia S.A
SA:AESB3
|
0.008x |
|
Clearpoint Neuro Inc
NASDAQ:CLPT
|
-0.197x |
|
Continental Holdings Corp
TW:3703
|
0.024x |
Annual Cash Flow Conversion Efficiency for EuBiologics Co. Ltd. (2021–2024)
The table below shows the annual cash flow conversion efficiency of EuBiologics Co. Ltd. from 2021 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-09-30 | ₩132.03 Billion | ₩43.21 Billion | 0.327x | +37.80% |
| 2023-09-30 | ₩111.37 Billion | ₩26.45 Billion | 0.238x | +340.46% |
| 2022-09-30 | ₩119.44 Billion | ₩6.44 Billion | 0.054x | +185.12% |
| 2021-09-30 | ₩120.00 Billion | ₩-7.60 Billion | -0.063x | -- |